Company intelligence / Profile preview

Amryt Pharma

Dublin, Ireland

Ownership: Private
Employees: ~151
Development stage: Other

Overview

Amryt built a strong portfolio of commercial and development assets for rare/orphan diseases. Its lead product Filsuvez received FDA approval after Chiesi’s acquisition. The company had multiple clinical programs and four marketed drugs prior to its acquisition by Chiesi Farmaceutici S.p.A.[1][2][3][5]

Therapeutic areas: Dermatology
Modalities: Small moleculesTopical gels[3][5]
Industry: Biotech

Beyond the preview

Go deeper on Amryt Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amryt Pharma.

Explore the full profile